A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
Researchers found adagrasib effective in suppressing cancer growth in both lungs and brain metastases, with a 90% intracranial disease control rate and 42% objective response rate. The median intracranial progression-free survival was 5.4 months, while the median overall survival reached 11.4 months.
The FRESCO-2 trial shows that fruquintinib significantly improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer. The median OS was 7.4 months with fruquintinib versus 4.8 months in the placebo arm.
Researchers at MD Anderson Cancer Center develop new methodology to analyze earliest precursor stages of multiple myeloma, revealing substantial genomic and transcriptional heterogeneity. The study identifies potential therapeutic targets and biomarkers for high-risk patients.
The study found an objective response rate of 61.3% with a median duration of response of 22.1 months in patients with high HER2 expression. The treatment showed promise in a significant unmet area of clinical need, providing a new option for patients with hard-to-treat HER2-positive cancers.
A Phase III trial found that axicabtagene ciloleucel (axi-cel) significantly improved overall survival and progression-free survival in patients with early relapsed or refractory large B-cell lymphoma, compared to standard therapy. The estimated four-year survival rate was 54.6% with axi-cel.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
A pan-cancer single-cell T cell atlas provides a detailed picture of the heterogeneity of T cells within the tumor microenvironment, revealing a previously undescribed stress response state that appears to be less effective at fighting cancer. This new discovery highlights the need for further understanding of how these states contribu...
The COMMANDS trial showed improved red blood cell counts and erythroid responses in transfusion-dependent patients with myelodysplastic syndromes, allowing the majority to no longer require regular blood transfusions. Luspatercept demonstrated superior effectiveness over epoetin alfa in this study.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
A Phase I trial of CD70-targeting CAR T cell therapy ALLO-316 demonstrates encouraging response rates and disease control rates in patients with metastatic ccRCC. The treatment had a manageable safety profile, with no cases of GVHD or ICANS observed.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...
Researchers found encouraging responses with revumenib for advanced acute leukemias with KMT2A rearrangements or NPM1 mutations. The overall response rate was 53%, with 78% of patients achieving clearance of measurable residual disease.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
Researchers at the University of Texas MD Anderson Cancer Center have discovered a new cell death mechanism called disulfidptosis that targets cancer cells with high expression of SLC7A11. Disulfidptosis is triggered by glucose starvation and can effectively suppress tumor growth without significant toxicity in normal tissues.
Patients with myelofibrosis experience significant symptom improvements when treated with momelotinib, including reduced spleen size and decreased transfusion dependency. The Phase III MOMENTUM trial reports meaningful benefits over standard therapy danazol.
Researchers at University of Texas M. D. Anderson Cancer Center develop a novel mRNA delivery system using extracellular vesicles, which can initiate collagen production in cells and has potential for other mRNA therapies
In a Phase I clinical trial, afami-cel achieved an objective response rate of 44% in patients with synovial sarcoma and 24% across all cancer types. The therapy demonstrated manageable toxicity and early activity in other cancer types, suggesting potential for solid tumors.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
The CodeBreaK 100 trial demonstrates meaningful anticancer activity with sotorasib in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer. The results show an objective response rate of 21.1% and a median time-to-response of 1.5 months.
The Andrew Sabin Family Foundation has donated $10 million to the James P. Allison Institute, a research and innovation hub aiming to unlock cancer cures. The gift will support elite scientists and post-doctoral programs to accelerate breakthroughs in immunobiology.
A new nanotechnology platform has successfully converted solid tumor cells into immune-activating targets, making them more receptive to immunotherapy. The approach uses a bispecific nanoconjugate to attach an immune-activating molecule to the surface of cancer cells, triggering an immune response.
Patients with non-metastatic soft tissue sarcoma can safely receive hypofractionated treatment over three weeks instead of five, achieving similar tumor control and no increased risk of wound complications. The study found comparable rates of major wound complications between the two treatment courses.
A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.
A Phase II study found that the combination of relatlimab and nivolumab was safe and completely cleared all viable tumor in 57% of patients with stage III melanoma before surgery. The overall pathologic response rate was 70%, with no grade 3 or 4 immune-related adverse events reported.
The EXTEND trial found that combining metastasis-directed radiation therapy with intermittent hormone therapy improved progression-free survival in men with oligometastatic prostate cancer. The treatment also prolonged the time men could safely maintain normal testosterone levels, preserving their quality of life.
A new CAR NK cell engineering approach requires two signals to eliminate target cells, improving tumor specificity and enhancing anti-tumor activity. This strategy mitigates NK cell exhaustion and fratricide, leading to better focus on and attack of only the tumor cells.
Researchers identified a specific gut bacterium responsible for antibiotic-induced GVHD after stem cell transplants. A sugar supplement was found to improve gut health by distracting the bacteria from attacking mucin in the intestinal lining, reducing complications such as GVHD.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
In an international clinical trial, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated and met its primary endpoint with a pathologic complete response rate of 50.6%.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Combination chemotherapy with FOLFIRINOX before surgery increased survival in patients with borderline resectable pancreatic cancer, outperforming FOLFIRINOX plus radiotherapy. The study demonstrated the effectiveness of neoadjuvant chemotherapy in improving outcomes for these patients.
The study found an overall response rate of 32% across all patients with EGFR exon 20 mutations, varying depending on the location of the mutation. Near-loop insertions showed a 46% overall response rate, while far-loop insertions had no response rate.
Researchers found higher AR signaling and better response rates for female patients treated with BRAF/MEK inhibitors. Blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.
Researchers developed a mathematical technique to measure total tumor-specific mRNA levels from bulk tumor sequencing data, associating higher mRNA levels with reduced patient survival. The study suggests this approach could serve as a prognostic biomarker for various cancers, guiding treatment selection.
A new genetic study published in Nature Genetics found that roughly one in five invasive breast cancers following ductal carcinoma in situ (DCIS) are genetically unrelated to the original DCIS. The findings provide a deeper understanding of DCIS biology and suggest that DCIS should be considered a risk factor for the development of inv...
Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.
A Phase II study found that immunotherapy before surgery improved median progression-free survival and overall survival for undifferentiated pleomorphic sarcoma and recurrent dedifferentiated liposarcoma patients. The treatment also showed an association between intratumoral B-cell receptor repertoire and survival.
The study found that combination chemoimmunotherapy with ibrutinib improved progression-free survival over standard chemoimmunotherapy in patients with previously untreated mantle cell lymphoma. The median PFS was 80.6 months with the ibrutinib combination versus 52.9 months in the control arm.
Researchers developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves immune checkpoint blockade efficacy. The Microbubble-assisted UltraSound-guided Immunotherapy of Cancer (MUSIC) approach demonstrated complete tumor eradication rates of up to 60% in breast cancer models.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Research by University of Texas M.D. Anderson Cancer Center reveals adolescent and young adult leukemia survivors have shorter life spans than those without cancer. The study found inferior long-term mortality outcomes persist even decades after treatment, impacting quality of life and overall survival.
Researchers at University of Texas M.D. Anderson Cancer Center identify IL-6 as a key player in immunotherapy toxicity. A novel strategy combining IL-6 blockade with immune checkpoint blockade shows promise in reducing autoimmune side effects while preserving antitumor efficacy.
Researchers found that vitamin E boosts immunotherapy responses by stimulating dendritic cell activity, leading to improved antigen presentation and enhanced antitumor immunity. Vitamin E treatment also showed promise in combining with cancer vaccines and immunogenic chemotherapies.
Researchers at MD Anderson have made significant advancements in treating neuroendocrine tumors with combination therapy, identified consensus subtypes for hepatocellular carcinoma to improve treatment selection, and found a targetable vulnerability in urothelial cancer due to MTAP loss.